Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 535
Filtrar
1.
BMC Endocr Disord ; 24(1): 55, 2024 Apr 28.
Artigo em Inglês | MEDLINE | ID: mdl-38679740

RESUMO

BACKGROUND: Glucocorticoids and sclerostin act as inhibitors of the Wnt signaling pathway, thereby hindering bone formation. Given the pathway's intricate association with mesenchymal stem cells, the hypothesis suggests that heightened sclerostin levels may be intricately linked to an augmentation in marrow adiposity induced by glucocorticoids. This study endeavored to delve into the nuanced relationship between circulating sclerostin and bone marrow adipose tissue in postmenopausal women grappling with glucocorticoid-induced osteoporosis (GIO). METHODS: In this cross-sectional study, 103 patients with autoimmune-associated diseases underwent glucocorticoid treatment, boasting an average age of 61.3 years (standard deviation 7.1 years). The investigation encompassed a thorough assessment, incorporating medical history, anthropometric data, biochemical analysis, and dual-energy X-ray absorptiometry measurements of lumbar and femoral bone mineral density (BMD). Osteoporosis criteria were established at a T-score of -2.5 or lower. Additionally, MR spectroscopy quantified the vertebral marrow fat fraction. RESULTS: BMD at the femoral neck, total hip, and lumbar spine showcased an inverse correlation with marrow fat fraction (r = -0.511 to - 0.647, P < 0.001). Serum sclerostin levels exhibited a positive correlation with BMD at various skeletal sites (r = 0.476 to 0.589, P < 0.001). A noteworthy correlation emerged between circulating sclerostin and marrow fat fraction at the lumbar spine (r = -0.731, 95% CI, -0.810 to -0.627, P < 0.001). Multivariate analysis brought to light that vertebral marrow fat fraction significantly contributed to sclerostin serum concentrations (standardized regression coefficient ß = 0.462, P < 0.001). Even after adjusting for age, body mass index, physical activity, renal function, BMD, and the duration and doses of glucocorticoid treatment, serum sclerostin levels maintained a significant correlation with marrow fat fraction. CONCLUSIONS: Circulating sclerostin levels exhibited a noteworthy association with marrow adiposity in postmenopausal women grappling with GIO.


Assuntos
Proteínas Adaptadoras de Transdução de Sinal , Adiposidade , Densidade Óssea , Medula Óssea , Glucocorticoides , Pós-Menopausa , Humanos , Feminino , Pessoa de Meia-Idade , Glucocorticoides/efeitos adversos , Estudos Transversais , Adiposidade/efeitos dos fármacos , Densidade Óssea/efeitos dos fármacos , Medula Óssea/efeitos dos fármacos , Medula Óssea/metabolismo , Idoso , Marcadores Genéticos , Biomarcadores/sangue , Biomarcadores/análise , Osteoporose Pós-Menopausa/sangue , Absorciometria de Fóton
2.
Int J Mol Sci ; 23(4)2022 Feb 19.
Artigo em Inglês | MEDLINE | ID: mdl-35216415

RESUMO

Obesity is an increasingly severe public health problem, which brings huge social and economic burdens. Increased body adiposity in obesity is not only tightly associated with type 2 diabetes, but also significantly increases the risks of other chronic diseases including cardiovascular diseases, fatty liver diseases and cancers. Adipogenesis describes the process of the differentiation and maturation of adipocytes, which accumulate in distributed adipose tissue at various sites in the body. The major functions of white adipocytes are to store energy as fat during periods when energy intake exceeds expenditure and to mobilize this stored fuel when energy expenditure exceeds intake. Brown/beige adipocytes contribute to non-shivering thermogenesis upon cold exposure and adrenergic stimulation, and thereby promote energy consumption. The imbalance of energy intake and expenditure causes obesity. Recent interest in epigenetics and signaling pathways has utilized small molecule tools aimed at modifying obesity-specific gene expression. In this review, we discuss compounds with adipogenesis-related signaling pathways and epigenetic modulating properties that have been identified as potential therapeutic agents which cast some light on the future treatment of obesity.


Assuntos
Adipogenia/efeitos dos fármacos , Fármacos Antiobesidade/farmacologia , Obesidade/tratamento farmacológico , Adiposidade/efeitos dos fármacos , Animais , Metabolismo Energético/efeitos dos fármacos , Humanos , Obesidade/metabolismo , Transdução de Sinais/efeitos dos fármacos , Termogênese/efeitos dos fármacos
3.
Fitoterapia ; 157: 105130, 2022 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-35051554

RESUMO

Petasites japonicus is one of the most popular edible wild plants in Japan. Many biological effects of P. japonicus have been reported, including anti-allergy, anti-inflammation, and anticancer effects. Although its anti-obesity effect has been reported in several studies, the most important component responsible for this activity has not been fully elucidated. On screening the components that suppress adipocyte differentiation in 3T3-F442A cells, we found that the extract of the flower buds of P. japonicus has anti-adipogenic effect. Among the known major components of P. japonicus, petasin exhibited a potent anti-adipogenic effect at an IC50 value of 0.95 µM. Quantitative analysis revealed that the active component responsible for most of the anti-adipogenic effects of P. japonicus extract is petasin. Petasin suppressed the expression of markers of mature adipocytes (PPARγ, C/EBPα, and aP2). However, as isopetasin and petasol, analogs of petasin, did not exhibit these effects, it indicates that a double bond at the C11-C12 position and an angeloyl ester moiety were essential for the activity. Petasin affected the late stage of adipocyte differentiation and inhibited the expression of lipid synthesis factors (ACC1, FAS, and SCD1). Additionally, it was revealed that petasin could be efficiently extracted using hexane with minimal amount of pyrrolizidine alkaloids, the toxic components. These findings indicate that P. japonicus extract containing petasin could be a promising food material for the prevention of obesity.


Assuntos
Adiposidade/efeitos dos fármacos , Obesidade/prevenção & controle , Petasites/química , Sesquiterpenos/farmacologia , Células 3T3/efeitos dos fármacos , Adipogenia/efeitos dos fármacos , Animais , Compostos Azo , Western Blotting , Corantes , Flores/química , Concentração Inibidora 50 , Japão , Camundongos , Polifenóis/análise , Alcaloides de Pirrolizidina/química , Reação em Cadeia da Polimerase em Tempo Real , Sesquiterpenos/química , Sesquiterpenos/isolamento & purificação , Relação Estrutura-Atividade
4.
Sci Rep ; 12(1): 484, 2022 01 10.
Artigo em Inglês | MEDLINE | ID: mdl-35013352

RESUMO

Treatment with a nicotinamide N-methyltransferase inhibitor (NNMTi; 5-amino-1-methylquinolinium) combined with low-fat diet (LD) promoted dramatic whole-body adiposity and weight loss in diet-induced obese (DIO) mice, rapidly normalizing these measures to age-matched lean animals, while LD switch alone was unable to restore these measures to age-matched controls in the same time frame. Since mouse microbiome profiles often highly correlate with body weight and fat composition, this study was designed to test whether the cecal microbiomes of DIO mice treated with NNMTi and LD were comparable to the microbiomes of age-matched lean counterparts and distinct from microbiomes of DIO mice maintained on a high-fat Western diet (WD) or subjected to LD switch alone. There were minimal microbiome differences between lean and obese controls, suggesting that diet composition and adiposity had limited effects. However, DIO mice switched from an obesity-promoting WD to an LD (regardless of treatment status) displayed several genera and phyla differences compared to obese and lean controls. While alpha diversity measures did not significantly differ between groups, beta diversity principal coordinates analyses suggested that mice from the same treatment group were the most similar. K-means clustering analysis of amplicon sequence variants by animal demonstrated that NNMTi-treated DIO mice switched to LD had a distinct microbiome pattern that was highlighted by decreased Erysipelatoclostridium and increased Lactobacillus relative abundances compared to vehicle counterparts; these genera are tied to body weight and metabolic regulation. Additionally, Parasutterella relative abundance, which was increased in both the vehicle- and NNMTi-treated LD-switched groups relative to the controls, significantly correlated with several adipose tissue metabolites' abundances. Collectively, these results provide a novel foundation for future investigations.


Assuntos
Inibidores Enzimáticos/administração & dosagem , Microbioma Gastrointestinal/efeitos dos fármacos , Nicotinamida N-Metiltransferase/antagonistas & inibidores , Nicotinamida N-Metiltransferase/metabolismo , Obesidade/dietoterapia , Obesidade/tratamento farmacológico , Tecido Adiposo/efeitos dos fármacos , Tecido Adiposo/metabolismo , Adiposidade/efeitos dos fármacos , Animais , Bactérias/classificação , Bactérias/efeitos dos fármacos , Bactérias/genética , Bactérias/isolamento & purificação , Peso Corporal/efeitos dos fármacos , Terapia Combinada , Dieta com Restrição de Gorduras , Humanos , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Obesos , Nicotinamida N-Metiltransferase/genética , Obesidade/metabolismo , Obesidade/microbiologia , Compostos de Quinolínio/administração & dosagem
5.
Life Sci ; 291: 120295, 2022 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-34998837

RESUMO

AIMS: High carbohydrate diet and carbonated soda consumption have individually been associated with metabolic dysfunction, with links to glucose and insulin homeostasis, affecting metabolic variables associated with feeding, satiety and adiposity. Our objective is to determine the combined effect of a high carbohydrate and carbonated soda diet on metabolic variables in male and female Wistar rats. MATERIALS AND METHODS: Thirty-two female and male weanlings were equally divided into four dietary groups; Control, Soda, High Carbohydrate diet (HCD), and High Carbohydrate diet/Soda (HCD/Soda), and fed ad libitum for fourteen weeks. Bodyweight, thoracic circumference, abdominal circumference and glucose was determined; Insulin, leptin, adiponectin, Tumor Necrotic Factor (TNF)-α, Interleukin (IL)-6 and lipid profile were assayed and used to determine the metabolic effects. KEY FINDINGS: Soda and HCD/Soda had increased body weight in male rats, while HCD-fed rats were reduced compared to respective controls. Abdominal circumference, total cholesterol and reduced HDL of Soda were elevated in both sexes. Although HCD/Soda groups had elevated abdominal circumference in both sexes, total cholesterol and reduced high-density lipoprotein (HDL) were both reduced in females. Insulin and malondialdehyde (MDA) concentrations in Soda-fed rats was significantly reduced, however, MDA was elevated in both sexes in HCD and HCD/Soda fed rats. Female HCD and HCD/Soda groups had a significant increase in glutathione (GSH) concentration and a significant reduction in catalase. TNF-α was increased in both Soda and HCD/Soda groups. SIGNIFICANCE: The results of this study suggest that HCD and Soda consumption results in alteration in phenotype and variables impacting metabolism.


Assuntos
Bebidas Gaseificadas/efeitos adversos , Carboidratos da Dieta/efeitos adversos , Obesidade/metabolismo , Adiponectina/metabolismo , Adiposidade/efeitos dos fármacos , Animais , Glicemia/metabolismo , Peso Corporal/fisiologia , Metabolismo dos Carboidratos/efeitos dos fármacos , Carboidratos , Dieta , Feminino , Insulina/metabolismo , Resistência à Insulina/fisiologia , Masculino , Malondialdeído/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Ratos , Ratos Wistar , Aumento de Peso/efeitos dos fármacos
6.
Acta Radiol ; 63(2): 245-252, 2022 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-33497273

RESUMO

BACKGROUND: Polyphenols in extra virgin olive oil (EVOO) have been found to reduce the expression of PPARγ2, inhibit adipocyte differentiation, and enhance the formation of osteoblasts from bone marrow stem cells. However, the underlying mechanisms of their action remain unknown. PURPOSE: To determine the sequential effects of EVOO on marrow fat expansion induced by estrogen deprivation using 3.0-T proton magnetic resonance (MR) spectroscopy in an ovariectomy (OVX) rabbit model of postmenopausal bone loss over a six-month period. MATERIAL AND METHODS: A total of 45 female New Zealand rabbits were equally divided into sham-operation, OVX controls, and OVX treated with EVOO for six months. Marrow fat fraction was measured by MR spectroscopy at baseline conditions, and three and six months postoperatively, respectively. Serum bone biomarkers, lumbar and femoral bone mineral density, microtomographic parameters, biomechanical properties, and quantitative parameters of marrow adipocytes were studied. RESULTS: OVX was associated with marrow adiposity in a time-dependent manner, accompanied with increased bone turnover and impaired bone mass and trabecular microarchitecture. In OVX rabbits, EVOO markedly alleviated trabecular bone loss and reduced the accumulation of lipid droplets including adipocyte size, density, and areas of fat deposits in the bone marrow. EVOO prevented such changes in terms of both marrow adiposity and bone remodeling. CONCLUSION: Early EVOO treatment may exert beneficial effects on bone by modulating marrow adiposity, which would support their protective effect against bone pathologies.


Assuntos
Adiposidade/efeitos dos fármacos , Medula Óssea/efeitos dos fármacos , Azeite de Oliva/farmacologia , Osteoporose Pós-Menopausa/fisiopatologia , PPAR gama/antagonistas & inibidores , Polifenóis/farmacologia , Espectroscopia de Prótons por Ressonância Magnética , Adiposidade/fisiologia , Animais , Fenômenos Biomecânicos , Densidade Óssea/efeitos dos fármacos , Medula Óssea/fisiologia , Células da Medula Óssea/citologia , Modelos Animais de Doenças , Feminino , Humanos , Osteogênese , Ovariectomia , Coelhos
7.
Am J Physiol Lung Cell Mol Physiol ; 322(1): L116-L128, 2022 01 01.
Artigo em Inglês | MEDLINE | ID: mdl-34850640

RESUMO

Obesity impairs host defense against Klebsiella pneumoniae, but responsible mechanisms are incompletely understood. To determine the impact of diet-induced obesity on pulmonary host defense against K. pneumoniae, we fed 6-wk-old male C57BL/6j mice a normal diet (ND) or high-fat diet (HFD) (13% vs. 60% fat, respectively) for 16 wk. Mice were intratracheally infected with Klebsiella, assayed at 24 or 48 h for bacterial colony-forming units, lung cytokines, and leukocytes from alveolar spaces, lung parenchyma, and gonadal adipose tissue were assessed using flow cytometry. Neutrophils from uninfected mice were cultured with and without 2-deoxy-d-glucose (2-DG) and assessed for phagocytosis, killing, reactive oxygen intermediates (ROI), transport of 2-DG, and glucose transporter (GLUT1-4) transcripts, and protein expression of GLUT1 and GLUT3. HFD mice had higher lung and splenic bacterial burdens. In HFD mice, baseline lung homogenate concentrations of IL-1ß, IL-6, IL-17, IFN-γ, CXCL2, and TNF-α were reduced relative to ND mice, but following infection were greater for IL-6, CCL2, CXCL2, and IL-1ß (24 h only). Despite equivalent lung homogenate leukocytes, HFD mice had fewer intraalveolar neutrophils. HFD neutrophils exhibited decreased Klebsiella phagocytosis and killing and reduced ROI to heat-killed Klebsiella in vitro. 2-DG transport was lower in HFD neutrophils, with reduced GLUT1 and GLUT3 transcripts and protein (GLUT3 only). Blocking glycolysis with 2-DG impaired bacterial killing and ROI production in neutrophils from mice fed ND but not HFD. Diet-induced obesity impairs pulmonary Klebsiella clearance and augments blood dissemination by reducing neutrophil killing and ROI due to impaired glucose transport.


Assuntos
Dieta , Glucose/metabolismo , Interações Hospedeiro-Patógeno , Infecções por Klebsiella/microbiologia , Klebsiella pneumoniae/fisiologia , Neutrófilos/metabolismo , Obesidade/microbiologia , Tecido Adiposo Branco/efeitos dos fármacos , Tecido Adiposo Branco/metabolismo , Adiposidade/efeitos dos fármacos , Animais , Carga Bacteriana/efeitos dos fármacos , Transporte Biológico/efeitos dos fármacos , Glicemia/metabolismo , Peso Corporal/efeitos dos fármacos , Medula Óssea/patologia , Líquido da Lavagem Broncoalveolar/citologia , Citocinas/metabolismo , Desoxiglucose/farmacologia , Dieta Hiperlipídica , Transportador de Glucose Tipo 1/genética , Transportador de Glucose Tipo 1/metabolismo , Transportador de Glucose Tipo 3/genética , Transportador de Glucose Tipo 3/metabolismo , Glicólise/efeitos dos fármacos , Interações Hospedeiro-Patógeno/efeitos dos fármacos , Infecções por Klebsiella/sangue , Infecções por Klebsiella/complicações , Klebsiella pneumoniae/efeitos dos fármacos , Contagem de Leucócitos , Pulmão/microbiologia , Pulmão/patologia , Masculino , Camundongos Endogâmicos C57BL , Neutrófilos/efeitos dos fármacos , Obesidade/sangue , Obesidade/complicações , Fagocitose/efeitos dos fármacos , Pneumonia/microbiologia , Pneumonia/patologia , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Baço/microbiologia
8.
Gut Microbes ; 13(1): 2004070, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34812123

RESUMO

The Developmental Origins of Health and Disease (DOHaD) concept has been proposed to explain the influence of environmental conditions during critical developmental stages on the risk of diseases in adulthood. The aim of this study was to compare the impact of the prenatal vs. postnatal environment on the gut microbiota in dams during the preconception, gestation and lactation periods and their consequences on metabolic outcomes in offspring. Here we used the cross-fostering technique, e.g. the exchange of pups following birth to a foster dam, to decipher the metabolic effects of the intrauterine versus postnatal environmental exposures to a polyphenol-rich cranberry extract (CE). CE administration to high-fat high-sucrose (HFHS)-fed dams improved glucose homeostasis and reduced liver steatosis in association with a shift in the maternal gut microbiota composition. Unexpectedly, we observed that the postnatal environment contributed to metabolic outcomes in female offspring, as revealed by adverse effects on adiposity and glucose metabolism, while no effect was observed in male offspring. In addition to the strong sexual dimorphism, we found a significant influence of the nursing mother on the community structure of the gut microbiota based on α-diversity and ß-diversity indices in offspring. Gut microbiota transplantation (GMT) experiments partly reproduced the observed phenotype in female offspring. Our data support the concept that the postnatal environment represents a critical window to influence future sex-dependent metabolic outcomes in offspring that are causally but partly linked with gut microbiome alterations.


Assuntos
Microbioma Gastrointestinal/fisiologia , Glucose/metabolismo , Caracteres Sexuais , Adiposidade/efeitos dos fármacos , Animais , Dieta Hiperlipídica/efeitos adversos , Feminino , Microbioma Gastrointestinal/efeitos dos fármacos , Intolerância à Glucose/metabolismo , Masculino , Fenômenos Fisiológicos da Nutrição Materna/fisiologia , Camundongos , Obesidade/tratamento farmacológico , Obesidade/metabolismo , Obesidade/microbiologia , Extratos Vegetais/administração & dosagem , Extratos Vegetais/farmacologia , Gravidez , Vaccinium macrocarpon/química , Aumento de Peso/efeitos dos fármacos
9.
Nutrients ; 13(11)2021 Oct 21.
Artigo em Inglês | MEDLINE | ID: mdl-34835957

RESUMO

Pre-pregnancy obesity is a contributing factor for impairments in offspring metabolic health. Interventional strategies during pregnancy are a potential approach to alleviate and/or prevent obesity and obesity related metabolic alterations in the offspring. Fish oil (FO), rich in omega-3 polyunsaturated fatty acids (n-3 PUFAs) exerts metabolic health benefits. However, the role of FO in early life remains still unknown. Hence, this study objective was to determine the effect of FO supplementation in mice from pre-pregnancy through lactation, and to study the post-natal metabolic health effects in gonadal fat and liver of offspring fed high fat (HF) diet with or without FO. Female C57BL6J mice aged 4-5 weeks were fed a HF (45% fat) diet supplemented with or without FO (30 g/kg of diet) and low fat (LF; 10% fat) pre-pregnancy through lactation. After weaning, offspring (male and female) from HF or FO dams either continued the same diet (HF-HF and FO-FO) or switched to the other diet (HF-FO and FO-HF) for 13 weeks, creating four groups of treatment, and LF-LF was used as a control group. Serum, gonadal fat and liver tissue were collected at termination for metabolic analyses. Offspring of both sexes fed HF with or without fish oil gained (p < 0.05) more weight post weaning, compared to LF-LF-fed mice. All the female offspring groups supplemented with FO had reduced body weight compared to the respective male groups. Further, FO-FO supplementation in both sexes (p < 0.05) improved glucose clearance and insulin sensitivity compared to HF-HF. All FO-FO fed mice had significantly reduced adipocyte size compared to HF-HF group in both male and females. Inflammation, measured by mRNA levels of monocyte chemoattractant protein 1 (Mcp1), was reduced (p < 0.05) with FO supplementation in both sexes in gonadal fat and in the liver. Markers of fatty acid synthesis, fatty acid synthase (Fasn) showed no sex specific differences in gonadal fat and liver of mice supplemented with HF. Female mice had lower liver triglycerides than male counterparts. Supplementation of FO in mice improved metabolic health of offspring by lowering markers of lipid synthesis and inflammation.


Assuntos
Dieta Hiperlipídica , Suplementos Nutricionais , Óleos de Peixe/farmacologia , Obesidade/patologia , Caracteres Sexuais , Adipocinas/sangue , Tecido Adiposo/metabolismo , Adiposidade/efeitos dos fármacos , Animais , Biomarcadores/metabolismo , Peso Corporal/efeitos dos fármacos , Ácidos Graxos Ômega-3/metabolismo , Feminino , Glucose/metabolismo , Inflamação/sangue , Metabolismo dos Lipídeos/efeitos dos fármacos , Masculino , Camundongos Endogâmicos C57BL , Obesidade/sangue , Gravidez , Triglicerídeos/metabolismo
10.
Int J Mol Sci ; 22(18)2021 Sep 14.
Artigo em Inglês | MEDLINE | ID: mdl-34576066

RESUMO

Papain is a proteolytic enzyme present in the leaves, fruits, roots, and latex of the Carica papaya (papaya) plant. Although it exhibits a wide range of activities, there are no reports on the anti-obesity effects of papain. This study examined the anti-obesity effect and obesity-involved anti-inflammatory mechanism of papain in in vivo and in vitro models using high-fat diet (HFD)-induced obese mice and 3T3-L1 preadipocytes. Oral administration of papain reduced HFD-induced weight of the body, liver, and adipose tissues of mice. Papain also reduced hepatic lipid accumulation and adipocyte size. Moreover, serum total cholesterol and triglyceride levels were markedly reduced in papain-treated mice. In addition, papain inhibited the differentiation of preadipocytes and oil accumulation in 3T3-L1 preadipocytes and rat primary preadipocytes. Mechanistically, papain significantly downregulated the protein levels of key adipogenesis regulators and reversed the expression of pro-inflammatory cytokines and adipokines in HFD-induced obese mice and 3T3-L1 preadipocytes. Papain also markedly enhanced activation of the AMP-activated protein kinase pathway in both models. Collectively, these results suggest that papain exerts anti-obesity effects in HFD-induced mice and 3T3-L1 preadipocytes by regulating levels of adipogenic factors involved in lipid metabolism and inflammation; thus, it could be useful in the prevention and treatment of obesity.


Assuntos
Proteínas Quinases Ativadas por AMP/metabolismo , Adipócitos/patologia , Dieta Hiperlipídica , Inflamação/patologia , Metabolismo dos Lipídeos/efeitos dos fármacos , Obesidade/metabolismo , Obesidade/patologia , Papaína/farmacologia , Células 3T3-L1 , Adipócitos/efeitos dos fármacos , Adipócitos/metabolismo , Adipogenia/efeitos dos fármacos , Adipocinas/metabolismo , Adiposidade/efeitos dos fármacos , Animais , Biomarcadores/metabolismo , Peso Corporal/efeitos dos fármacos , Ativação Enzimática/efeitos dos fármacos , Fígado Gorduroso/patologia , Proteína Forkhead Box O1/metabolismo , Hipertrofia , Lipídeos/sangue , Fígado/efeitos dos fármacos , Fígado/patologia , Macrófagos/efeitos dos fármacos , Macrófagos/patologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Obesos , Tamanho do Órgão/efeitos dos fármacos , Sirtuína 1/metabolismo
11.
Nutrients ; 13(7)2021 Jul 20.
Artigo em Inglês | MEDLINE | ID: mdl-34371987

RESUMO

It was previously observed that in a population of a high-income country, dietary multiple micronutrient supplementation in pregnancy was associated with an increased risk of gestational diabetes (GDM) and increased offspring size at birth. In this follow-up study, we investigated whether similar changes are observed with dietary iron supplementation. For this we used the prospective Cambridge Baby Growth Study with records of maternal GDM status, nutrient supplementation, and extensive offspring birth size measurements. Maternal iron supplementation in pregnancy was associated with GDM development (risk ratio 1.67 (1.01-2.77), p = 0.048, n = 677) as well as offspring size and adiposity (n = 844-868) at birth in terms of weight (ß' = 0.078 (0.024-0.133); p = 0.005), head circumference (ß' = 0.060 (0.012-0.107); p = 0.02), body mass index (ß' = 0.067 (0.014-0.119); p = 0.01), and various skinfold thicknesses (ß' = 0.067-0.094; p = 0.03-0.003). In a subset of participants for whom GDM statuses were available, all these associations were attenuated by adjusting for GDM. Iron supplementation also attenuated the associations between multiple micronutrient supplementation and these same measures. These results suggest that iron supplementation may mediate the effects associated with multiple micronutrient supplementation in pregnancy in a high-income country, possibly through the increased risk of developing GDM.


Assuntos
Peso ao Nascer/efeitos dos fármacos , Suplementos Nutricionais , Ferro da Dieta/efeitos adversos , Fenômenos Fisiológicos da Nutrição Materna/efeitos dos fármacos , Micronutrientes/efeitos adversos , Adiposidade/efeitos dos fármacos , Adulto , Índice de Massa Corporal , Diabetes Gestacional/induzido quimicamente , Diabetes Gestacional/fisiopatologia , Feminino , Seguimentos , Humanos , Recém-Nascido , Ferro da Dieta/administração & dosagem , Masculino , Micronutrientes/administração & dosagem , Gravidez , Estudos Prospectivos , Dobras Cutâneas
12.
Biomed Pharmacother ; 142: 111969, 2021 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-34333285

RESUMO

p-Coumaric acid (PC), a naturally occurring phytochemical, possesses antioxidant and anti-inflammatory properties; however, the mechanisms underlying its protective effects against obesity-related metabolic dysfunction are largely unknown. Here, we treated C57BL/6J mice to a high-fat diet (HFD) with or without PC (10 mg/kg body weight/day) for 16 weeks to determine whether PC ameliorates HFD-induced obesity, insulin resistance, inflammation, and non-alcoholic fatty liver disease (NAFLD). We found no significant differences in food intake and body weight between the groups. However, PC-treated mice showed significantly lower white adipose tissue (WAT) weight, adipocyte size, and plasma leptin level, which were associated with decreased lipogenic enzyme activity and mRNA expression of their genes in the epididymal WAT. Moreover, hepatic lipogenic enzymes activities and expression of their genes and proteins were decreased with concomitant increases in hepatic fatty acid oxidation and mRNA expression of its gene; fecal lipid excretion was significantly increased, resulting in decreased liver weight, hepatic lipid levels, lipid droplet accumulation, and plasma aspartate aminotransferase and lipid levels. Additionally, PC-treated mice showed lower fasting blood glucose, plasma resistin, and MCP-1 levels, HOMA-IR, and mRNA expression of inflammatory genes in the epididymal WAT and liver. Our findings reveal potential mechanisms underlying the action of PC against HFD-induced adiposity, NAFLD, and other metabolic disturbances.


Assuntos
Ácidos Cumáricos/farmacologia , Inflamação/prevenção & controle , Hepatopatia Gordurosa não Alcoólica/prevenção & controle , Obesidade/prevenção & controle , Adiposidade/efeitos dos fármacos , Animais , Anti-Inflamatórios/farmacologia , Antioxidantes/farmacologia , Glicemia/efeitos dos fármacos , Dieta Hiperlipídica/efeitos adversos , Resistência à Insulina , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Resistina/sangue
13.
Peptides ; 144: 170608, 2021 10.
Artigo em Inglês | MEDLINE | ID: mdl-34265369

RESUMO

Appetite is closely regulated not only by gut hormonal and neuronal peptides but also by exogenous peptides derived from food proteins. Food proteins are now recognized to contain many thousands of bioactive compounds that provide additional health benefits beyond their nutritional effects. Bioactive peptides are beneficial to the life and/or to regulate physiological functions. Although animal protein products have been widely applied in the food industry, exploring the possibilities of developing functional foods based on plant protein-derived peptides is considered attractive for achieving sustainable development goals. In addition, peptides from plant proteins have the potential to treat numerous diseases or risk factors and may therefore facilitate a healthy life expectancy. In this review, we discuss the identified plant-based bioactive peptides and their appetite regulating effects. Plant-based bioactive peptides may provide new opportunities to discover novel approaches that can improve and prevent diseases in a sustainable environment.


Assuntos
Regulação do Apetite/efeitos dos fármacos , Peptídeos/farmacologia , Proteínas de Plantas/farmacologia , Adiposidade/efeitos dos fármacos , Animais , Estimulantes do Apetite/farmacologia , Ingestão de Alimentos/efeitos dos fármacos , Humanos , Fragmentos de Peptídeos/farmacologia , Peptídeos/química , Proteínas de Plantas/química , Ribulose-Bifosfato Carboxilase/farmacologia
14.
Int J Biol Macromol ; 187: 651-663, 2021 Sep 30.
Artigo em Inglês | MEDLINE | ID: mdl-34303740

RESUMO

An efficient extraction method of Auricularia auricula polysaccharides (AAPs) by neutral protease was developed and optimized by response surface methodology. AAPs were graded by stepwise ethanol precipitation, the fraction with high recovery rate and strong radical scavenging rate were obtained, then its antioxidant and lipid lowering effect were studied using Caenorhabditis elegans as model organism. The extract yield and ABTS+ scavenging rates of AAPs could reach 14.90% and 86.0% at 50 °C, 75 mL/g of liquid-to-material ratio and pH 9.0. AAP3 obtained by 15% ethanol was a heteropolysaccharide comprised of mannose, glucose, glucuronic acid, xylose, galactose and glucosamine. AAP3 could significantly prolong the lifespan of C. elegans and enhance the activity of antioxidant enzymes including superoxide dismutase (SOD), catalases (CAT) at 0.25 mg/mL (p < 0.05). The qRT-PCR results showed that AAP3 could up regulate mRNA expression levels of daf-16 and skn-1 (>1.6 fold) at 0.25 mg/mL. Besides, AAP3 could significantly reduce the level of body fat and triglyceride in C. elegans (p < 0.05). These studies demonstrated that A. auricula polysaccharides prepared by neutral protease had a prominent protective effect to the damage induced by the intracellular free radical generating agents.


Assuntos
Antioxidantes/farmacologia , Auricularia/enzimologia , Caenorhabditis elegans/efeitos dos fármacos , Polissacarídeos Fúngicos/farmacologia , Hipolipemiantes/farmacologia , Metaloendopeptidases/metabolismo , Adiposidade/efeitos dos fármacos , Animais , Antioxidantes/isolamento & purificação , Benzotiazóis/química , Compostos de Bifenilo/química , Caenorhabditis elegans/genética , Caenorhabditis elegans/metabolismo , Proteínas de Caenorhabditis elegans/genética , Proteínas de Caenorhabditis elegans/metabolismo , Fracionamento Químico , Regulação para Baixo , Polissacarídeos Fúngicos/isolamento & purificação , Hipolipemiantes/isolamento & purificação , Picratos/química , Ácidos Sulfônicos/química , Triglicerídeos/metabolismo
15.
Food Funct ; 12(13): 6083-6090, 2021 Jul 07.
Artigo em Inglês | MEDLINE | ID: mdl-34047312

RESUMO

This study investigated the effects of germinated millet flour on adipogenesis, insulin resistance, glucose tolerance and thyroid function in Wistar rats fed with a high-fat high-fructose diet (HFHF). The experiment was divided into two phases. Phase 1: control group, which received an AIN-93M diet (n = 10) and HFHF group (n = 20), which received a diet rich in saturated fat (31%) and fructose (20%), for eight weeks. Phase 2: intervention: the control group maintained the AIN-93M diet (n = 10) and the HFHF group was divided into two groups: the HFHF (n = 10) and the germinated millet group (n = 10), for 10 weeks. The germinated millet flour maintained (p > 0, 05) the plasma levels of thyroid hormones, increased (p < 0.05) the insulin receptor (INSR) mRNA expression, protein kinase B (AKT) mRNA expression and the phospho-AKT1 protein concentration, phosphofructokinase (PFK) mRNA, pyruvate kinase (PK) mRNA and activated protein kinase (AMPK) mRNA expression, and the brown adipose tissue and reduced (p < 0.05) the glucose triglyceride index (TyG), glucose, insulin, HOMA-IR and hypercorticosteronemia, compared to the HFHF group. These effects contributed to reduce the gluconeogenesis, hyperinsulinemia and adiposity. Thus, germinated millet flour is a good alternative for modulating the adipogenesis and glucose metabolism, without interfering with the thyroid hormones, in rats with an insulin resistance condition with a high-fat high-fructose diet.


Assuntos
Adipogenia/efeitos dos fármacos , Glucose/metabolismo , Hipoglicemiantes/farmacologia , Pennisetum , Glândula Tireoide/metabolismo , Tecido Adiposo Marrom/metabolismo , Adiposidade/efeitos dos fármacos , Animais , Dieta Hiperlipídica/efeitos adversos , Farinha , Frutose/administração & dosagem , Gluconeogênese/efeitos dos fármacos , Humanos , Hipoglicemiantes/química , Insulina/metabolismo , Resistência à Insulina , Masculino , Milhetes , Proteínas Proto-Oncogênicas c-akt/metabolismo , Ratos , Ratos Wistar , Receptor de Insulina/metabolismo
16.
Life Sci ; 278: 119550, 2021 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-33932442

RESUMO

AIMS: Vitamin (Vit) D regulates various organic processes, including adipose tissue morphofunction and lipid metabolism. Studies indicate that Vit D bioavailability is reduced in obesity, which could contribute to obesity development; however, the effects of Vit D supplementation on increased adiposity in western diet (WD)-obese rats (an experimental model that better resembles the obesogenic human obesity condition) have not been studied, to date. Thus, we hypothesized that Vit D supplementation following the induction of obesity in WD rats might reduce their body weight (BW) and adiposity. MAIN METHODS: Male Wistar rats were fed on a standard chow [control (CTL) group] or a WD to induce obesity (WD group), from 21 to 59 days of age. Subsequently, from 60 to 90-days, half of the CTL and of the WD rats were randomly submitted, or not, to oral Vit D supplementation (CTL-VD and WD-VD groups, respectively). KEY FINDINGS: At 91 days of age, WD rats were obese, displaying higher abdominal circumference and white fat stores, dyslipidemia, hyperleptinemia and greater plasma levels of tumor necrosis factor (TNF)-α. Vit D supplementation decreased BW gain, abdominal fat deposition and ameliorated the plasma lipid profile in WD-VD rats. These effects were accompanied by reductions in leptinemia and in circulating TNF-α levels in these rodents. SIGNIFICANCE: Vit D supplementation, following the induction of obesity, may represent a good strategy to attenuate BW gain and abdominal adiposity, and ameliorate the plasma lipid profile in WD rats. These effects may be mediated, at least in part, by reductions in circulating levels of leptin and TNF-α.


Assuntos
Adiposidade/efeitos dos fármacos , Dieta Ocidental/efeitos adversos , Obesidade/tratamento farmacológico , Fator de Necrose Tumoral alfa/sangue , Vitamina D/uso terapêutico , Vitaminas/uso terapêutico , Animais , Peso Corporal/efeitos dos fármacos , Lipídeos/sangue , Masculino , Obesidade/sangue , Obesidade/etiologia , Obesidade/fisiopatologia , Ratos Wistar
17.
Physiol Res ; 70(2): 161-168, 2021 04 30.
Artigo em Inglês | MEDLINE | ID: mdl-33992045

RESUMO

This paper reviews provenance, chemical composition and properties of tea (Camelia sinensis L.) and coffee (Coffee arabica, L. and Coffeacaniphora, L.), their general health effects, as well as the currently available knowledge concerning their action on fat storage, physiological mechanisms of their effects, as well as their safety and recommended dosage for treatment of obesity. Both tea and coffee possess the ability to promote health and to prevent, to mitigate and to treat numerous disorders. This ability can be partially due to presence of caffeine in both plants. Further physiological and medicinal effects could be explained by other molecules (theaflavins, catechins, their metabolites and polyphenols in tea and polyphenol chlorogenic acid in coffee). These plants and plant molecules can be efficient for prevention and treatment of numerous metabolic disorders including metabolic syndrome, cardiovascular diseases, type 2 diabetes and obesity. Both plants and their constituents can reduce fat storage through suppression of adipocyte functions, and support of gut microbiota. In addition, tea can prevent obesity via reduction of appetite, food consumption and food absorption in gastrointestinal system and through the changes in fat metabolism.


Assuntos
Fármacos Antiobesidade/administração & dosagem , Café , Nível de Saúde , Obesidade/prevenção & controle , Compostos Fitoquímicos/administração & dosagem , Chá , Adiposidade/efeitos dos fármacos , Animais , Fármacos Antiobesidade/efeitos adversos , Regulação do Apetite/efeitos dos fármacos , Café/efeitos adversos , Humanos , Metabolismo dos Lipídeos/efeitos dos fármacos , Obesidade/diagnóstico , Obesidade/fisiopatologia , Compostos Fitoquímicos/efeitos adversos , Chá/efeitos adversos , Aumento de Peso/efeitos dos fármacos
18.
BMC Endocr Disord ; 21(1): 81, 2021 Apr 26.
Artigo em Inglês | MEDLINE | ID: mdl-33902531

RESUMO

BACKGROUND: Hyperprolactinaemia might cause adverse metabolic effects. The aim of our study was to compare parameters of body composition, glucose and lipid metabolism between untreated patients with prolactinoma and controls and to assess changes after initiation of cabergoline. METHODS: Case-control study with a retrospectively analyzed follow-up in patients with prolactinoma after initiation of cabergoline therapy. RESULTS: 21 patients with prolactinoma (9 micro- and 12 macroprolactinomas; 7 females) and 30 controls were analyzed. Patients with prolactinoma had significantly higher BMI than controls; fat mass did not differ between groups. Only men - but not women - with prolactinoma had significantly higher fat mass at all six sites measured compared to controls. Levels of LDL (130 (107-147.5) vs. 94.5 (80-127.5) mg/dl, p < 0.001) were significantly higher, levels of HDL (56 ± 16.7 vs. 69.2 ± 14.6 mg/dl, p = 0.004) significantly lower than in controls. Fasting glucose, HOMA-IR, HbA1c, adiponectin, CRP, and homocysteine did not differ between groups. After a median of 10 weeks (IQR 7-18 weeks) after initiation of cabergoline, total (from 212.5 ± 36.2 to 196.9 ± 40.6 mg/dl, p = 0.018) and LDL cholesterol (130 (107-147.5) to 106.5 (94.3-148) mg/dl, p = 0.018) had significantly decreased. Analyzing men and women separately, this change occurred in men only. CONCLUSIONS: Reasons for the association between prolactin and metabolic parameters include direct effects of prolactin on adipose tissue, hyperprolactinaemia-triggered hypogonadism and dopamine-agonist therapy per se. Altered lipid metabolism in patients with prolactinoma might imply an increased cardiovascular risk, highlighting the necessity to monitor metabolic parameters in these patients.


Assuntos
Composição Corporal , Hiperprolactinemia/metabolismo , Metabolismo dos Lipídeos , Neoplasias Hipofisárias/metabolismo , Prolactinoma/metabolismo , Adiposidade/efeitos dos fármacos , Adiposidade/fisiologia , Adulto , Áustria , Composição Corporal/efeitos dos fármacos , Índice de Massa Corporal , Cabergolina/uso terapêutico , Estudos de Casos e Controles , Dislipidemias/tratamento farmacológico , Dislipidemias/etiologia , Dislipidemias/metabolismo , Feminino , Seguimentos , Humanos , Hiperprolactinemia/complicações , Hiperprolactinemia/tratamento farmacológico , Metabolismo dos Lipídeos/efeitos dos fármacos , Masculino , Pessoa de Meia-Idade , Sobrepeso/tratamento farmacológico , Sobrepeso/etiologia , Sobrepeso/metabolismo , Neoplasias Hipofisárias/complicações , Neoplasias Hipofisárias/tratamento farmacológico , Prolactinoma/complicações , Prolactinoma/tratamento farmacológico , Estudos Retrospectivos , Adulto Jovem
19.
Curr Obes Rep ; 10(2): 162-180, 2021 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-33792853

RESUMO

PURPOSE OF REVIEW: Evidence from observational studies suggests that obesity is associated with low vitamin D. As both obesity and hypovitaminosis D present an alarmingly increased prevalence worldwide, there is an intense research interest to clarify all aspects of this association. This review summarizes current evidence from meta-analyses investigating vitamin D status in obesity, including the effects of weight loss and bariatric surgery on vitamin D status and the outcomes of vitamin D supplementation on body weight. We also discuss potential pathophysiologic mechanisms and important controversies. RECENT FINDINGS: Data from meta-analyses consistently support an inverse association of vitamin D levels with body weight. However, the impact of weight loss on improving vitamin D status is small, while studies on the supplementation with vitamin D after bariatric surgery have shown conflicting results regarding vitamin D status. Moreover, interventional studies do not support a beneficial effect of vitamin D supplementation on body weight. These findings warrant a cautious interpretation due to important methodological limitations and confounding factors, such as high heterogeneity of studies, variable methods of determination of vitamin D and definition of deficiency/insufficiency, use of various adiposity measures and definitions of obesity, and inadequate adjustment for confounding variables influencing vitamin D levels. The underlying pathogenetic mechanisms associating low vitamin D in obesity include volumetric dilution, sequestration into adipose tissue, limited sunlight exposure, and decreased vitamin D synthesis in the adipose tissue and liver. Experimental studies have demonstrated that low vitamin D may be implicated in adipose tissue differentiation and growth leading to obesity either by regulation of gene expression or through modulation of parathyroid hormone, calcium, and leptin. Obesity is associated with low vitamin D status but weight loss has little effect on improving this; vitamin D supplementation is also not associated with weight loss. Evidence regarding vitamin D status after bariatric surgery is contradicting. The link between vitamin D and obesity remains controversial due to important limitations and confounding of studies. More research is needed to clarify the complex interplay between vitamin D and adiposity.


Assuntos
Obesidade , Vitamina D , Tecido Adiposo/metabolismo , Adiposidade/efeitos dos fármacos , Cirurgia Bariátrica , Peso Corporal , Bases de Dados Factuais , Suplementos Nutricionais , Humanos , Obesidade/epidemiologia , Vitamina D/uso terapêutico , Deficiência de Vitamina D/epidemiologia , Redução de Peso
20.
Sci Rep ; 11(1): 5637, 2021 03 11.
Artigo em Inglês | MEDLINE | ID: mdl-33707534

RESUMO

Obesity is a large and growing global health problem with few effective therapies. The present study investigated metabolic and physiological benefits of nicotinamide N-methyltransferase inhibitor (NNMTi) treatment combined with a lean diet substitution in diet-induced obese mice. NNMTi treatment combined with lean diet substitution accelerated and improved body weight and fat loss, increased whole-body lean mass to body weight ratio, reduced liver and epididymal white adipose tissue weights, decreased liver adiposity, and improved hepatic steatosis, relative to a lean diet substitution alone. Importantly, combined lean diet and NNMTi treatment normalized body composition and liver adiposity parameters to levels observed in age-matched lean diet control mice. NNMTi treatment produced a unique metabolomic signature in adipose tissue, with predominant increases in ketogenic amino acid abundance and alterations to metabolites linked to energy metabolic pathways. Taken together, NNMTi treatment's modulation of body weight, adiposity, liver physiology, and the adipose tissue metabolome strongly support it as a promising therapeutic for obesity and obesity-driven comorbidities.


Assuntos
Composição Corporal , Restrição Calórica , Inibidores Enzimáticos/farmacologia , Nicotinamida N-Metiltransferase/antagonistas & inibidores , Tecido Adiposo Branco/patologia , Adiposidade/efeitos dos fármacos , Animais , Biomarcadores/sangue , Composição Corporal/efeitos dos fármacos , Peso Corporal/efeitos dos fármacos , Epididimo/patologia , Fígado Gorduroso/sangue , Fígado/efeitos dos fármacos , Fígado/patologia , Masculino , Metaboloma/efeitos dos fármacos , Metabolômica , Camundongos Endogâmicos C57BL , Camundongos Obesos , Nicotinamida N-Metiltransferase/metabolismo , Magreza/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA